Patents by Inventor Raygene Michaël MARTIER

Raygene Michaël MARTIER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAi induced C9ORF72 suppression for the treatment of ALS/FTD
    Publication number: 20240398988
    Abstract: The present invention provides for specific target RNA sequences that can in particular be applied in RNAi based gene therapy approaches for the treatment of ALS and/or FTD. These specific target RNA sequences were found by selecting target RNA sequences that were conserved in the C9ORF72 target RNA sequence and were shown to provide for efficient silencing. Also are provided combinations of target RNA sequences that are useful in the treatment of ALS and/or FTD.
    Type: Application
    Filed: July 4, 2024
    Publication date: December 5, 2024
    Applicant: uniQure IP B.V.
    Inventors: Raygene Michaël Martier, Pavlina Stefanova Konstantinova
  • RNAI INDUCED REDUCTION OF ATAXIN-3 FOR THE TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 3
    Publication number: 20220010314
    Abstract: The current invention relates to gene therapy approaches for the treatment of SCA3, in particular RNAi based gene therapy approaches utilizing a total knockdown approach. The inventors provide for selected target regions and/or target sequences for which highly efficient knockdown of the ATXN3 gene expression can be advantegeously obtained in human neuronal cells and in mouse models relevant for SCA3.
    Type: Application
    Filed: May 13, 2021
    Publication date: January 13, 2022
    Inventors: Melvin Maurice EVERS, Pavlina Stefanova KONSTANTINOVA, Raygene Michaël MARTIER
  • RNAI INDUCED C9ORF72 SUPPRESSION FOR THE TREATMENT OF ALS/FTD
    Publication number: 20210330813
    Abstract: The present invention provides for specific target RNA sequences that can in particular be applied in RNAi based gene therapy approaches for the treatment of ALS and/or FTD. These specific target RNA sequences were found by selecting target RNA sequences that were conserved in the C9ORF72 target RNA sequence and were shown to provide for efficient silencing. Also are provided combinations of target RNA sequences that are useful in the treatment of ALS and/or FTD.
    Type: Application
    Filed: March 9, 2021
    Publication date: October 28, 2021
    Inventors: Raygene Michaël MARTIER, Pavlina Stefanova KONSTANTINOVA
  • RNAi induced reduction of ataxin-3 for the treatment of Spinocerebellar ataxia type 3
    Publication number: 20200199625
    Abstract: The current invention relates to gene therapy approaches for the treatment of SCA3, in particular RNAi based gene therapy approaches utilizing a total knockdown approach. The inventors provide for selected target regions and/or target sequences for which highly efficient knockdown of the ATXN3 gene expression can be advantageously obtained in human neuronal cells and in mouse models relevant for SCA3.
    Type: Application
    Filed: November 14, 2019
    Publication date: June 25, 2020
    Applicant: uniQure IP B.V.
    Inventors: Melvin Maurice EVERS, Pavlina Stefanova KONSTANTINOVA, Raygene Michael MARTIER